Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cellectis (CLLS) Liabilities and Shareholders Equity (2016 - 2025)

Cellectis (CLLS) has 6 years of Liabilities and Shareholders Equity data on record, last reported at $261.2 million in Q4 2022.

  • For Q4 2022, Liabilities and Shareholders Equity changed N/A year-over-year to $261.2 million; the TTM value through Dec 2022 reached $762.1 million, down 8.6%, while the annual FY2022 figure was $261.2 million, N/A changed from the prior year.
  • Liabilities and Shareholders Equity reached $261.2 million in Q4 2022 per CLLS's latest filing, down from $500.8 million in the prior quarter.
  • Across five years, Liabilities and Shareholders Equity topped out at $500.8 million in Q4 2018 and bottomed at $261.2 million in Q4 2022.